Peter Burke, MD
Cardiovascular Disease · Lansing, MINPI 1770605198
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Johnson & Johnson at 55.7% of the total. Reporting peaked in 2022 at $17,679 and has fallen 95.8% since, to $737 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 550 payments — averaging $67.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$21K
- Medtronic$5K
- Inari Medical, Inc.$4K
- Novartis$731
- Amgen$693
- Pfizer$576
- plus $5K from 36 others
Across 111 payments — averaging $807.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$57K
- Stryker$33K
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$19,21052%
- Travel & lodging$6,78118%
- Food & beverage$10,74229%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$19,617
- FLOWTRIEVER CATHETER, S$3,493
- CT THROMBECTOMY SYSTEM KIT$3,272
- IN.PACT Admiral$2,739
- Abre$668
- TurboHawk$269
- CARDIOMEMS$146
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$116
- (6571) Eagle Eye$108
- CLOTTRIEVER BOLD CATHETER$105
- AMVUTTRA$104
How this compares
$37,046 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 278 | $329,037 |
| XareltoRivaroxaban | 181 | $196,392 |
| JardianceEmpagliflozin | 121 | $122,428 |
| Repatha SureclickEvolocumab | 72 | $87,281 |
| EntrestoSacubitril/Valsartan | 45 | $52,682 |
| FarxigaDapagliflozin Propanediol | 45 | $49,055 |
| Praluent PenAlirocumab | 22 | $24,533 |
| Repatha SyringeEvolocumab | 19 | $20,943 |
| OzempicSemaglutide | 11 | $19,688 |
| MultaqDronedarone Hcl | 11 | $17,671 |
| Flecainide Acetate | 82 | $6,184 |
| Metoprolol Succinate | 333 | $5,981 |
| Rosuvastatin Calcium | 201 | $4,949 |
| Atorvastatin Calcium | 246 | $4,741 |
| Ezetimibe | 148 | $4,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $576 | $329,037278 claims |
| Johnson & JohnsonXarelto | $20,643 | $196,392181 claims |
| Boehringer IngelheimJardiance | $551 | $122,428121 claims |
| NovartisEntresto | $731 | $52,68245 claims |
| AstraZenecaFarxiga | $550 | $49,05545 claims |
| Novo NordiskOzempic | $86 | $19,68811 claims |
| Sanofi-aventis U.S. LLCMultaq | $191 | $17,67111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Lansing
- David StroblLansing$445K
- Chad LinkLansing$315K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- Herman KadoSouthfield$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.